Compare VIRT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIRT | EWTX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2015 | 2021 |
| Metric | VIRT | EWTX |
|---|---|---|
| Price | $35.46 | $23.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $41.43 | $37.30 |
| AVG Volume (30 Days) | 731.5K | ★ 1.3M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | ★ 132.69 | N/A |
| EPS | ★ 4.62 | N/A |
| Revenue | ★ $2,694,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.68 | ★ N/A |
| Revenue Growth | ★ 41.05 | N/A |
| 52 Week Low | $31.89 | $10.60 |
| 52 Week High | $45.77 | $35.50 |
| Indicator | VIRT | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 62.19 |
| Support Level | $34.16 | $22.51 |
| Resistance Level | $35.89 | $26.30 |
| Average True Range (ATR) | 0.86 | 1.46 |
| MACD | 0.07 | -0.10 |
| Stochastic Oscillator | 77.99 | 60.25 |
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.